UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
 
 
FORM 8-K

CURRENT REPORT
 
 
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 12, 2010

MEDASORB TECHNOLOGIES CORPORATION
(Exact name of registrant as specified in its charter)

Nevada
  
000-51038
  
98-0373793
(State or other jurisdiction of
incorporation)
  
(Commission File Number)
  
(I.R.S. Employer Identification
Number)

7 Deer Park Drive, Suite K
Monmouth Junction, New Jersey 08852
(Address of principal executive office) (Zip Code)

(732) 329-8885
Registrant’s telephone number, including area code:

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.below):

o      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13c-4(c))
 
 
 
 
 
Item 7.01 Regulation FD Disclosure.
 
Officers of Medasorb Technologies Corporation (the “Company”) expect to participate in a presentation with analysts and investors during the Biotech Showcase Conference (the “Biotech Conference”), being held January 12, 2010. A copy of the presentation materials to be made available at the Biotech Conference and at any one-on-one investor meetings is being furnished as Exhibit 99.1 hereto.
 
The information in this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statement and Exhibits.
  
(a)
Financial Statements of Business Acquired.
Not applicable.

(b)
Pro Forma Financial Information.
Not applicable.

(c)
Shell company transactions.
None.

(d)
Exhibits.
99.1
Slide presentation presented at the Biotech Showcase Conference on January 12, 2010. The slide presentation is furnished and not filed pursuant to Instruction B.2 of Form 8-K.

 
 
 
 
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

 
Medasorb Technologies Corporation
       
 
By:
 /s/ David Lamadrid
  
   
Name: David Lamadrid
  
   
Title: Chief Financial Officer
  
 
Dated: January 13, 2010